<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02767674</url>
  </required_header>
  <id_info>
    <org_study_id>JSPH-002</org_study_id>
    <nct_id>NCT02767674</nct_id>
  </id_info>
  <brief_title>Trial of R-GemOx Versus R-miniCHOP Regimen in First-line Treatment of Elderly Diffuse Large B Cell Lymphoma</brief_title>
  <official_title>Phase III,Randomized Controlled Trial of R-GemOx Versus R-miniCHOP Regimen in First-line Treatment of Elderly Diffuse Large B Cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The First Affiliated Hospital with Nanjing Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The First Affiliated Hospital with Nanjing Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate efficacy and safety of R-GemOx Versus R-miniCHOP
      as first-line treatment of elderly patients with Diffuse large B cell lymphoma
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Gemcitabine and Oxaliplatin(GemOx) shows effective activity in patients with relapsed diffuse
      large-cell lymphoma and other solid tumors. Our Previous study showed that two-weekly regimen
      of rituximab combined with GemOx regimen acheived comparable response rate to R-miniCHOP.The
      investigators therefore design this open-label,phase III and random trial to compared the
      safety and efficacy of R-Gemox versus R-miniCHOP as first-line treatment of elderly patients
      with diffuse large B cell lymphoma.

      Primary Outcome Measures:

      • 2-year overall survival rate

      Secondary Outcome Measures:

        -  2-year progression free survival rate

        -  overall response rate

        -  safety and toxicity Enrollment:258 Study Start Date: June 2016 Primary Completion Date:
           June 2019
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">July 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>2-year overall survival rate</measure>
    <time_frame>One year</time_frame>
    <description>from the date of inclusion to date of death, irrespective of cause</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>2-year progression free survival rate</measure>
    <time_frame>One year</time_frame>
    <description>from date of inclusion to date of progression, relapse, or death from any causePFS：from date of inclusion to date of progression, relapse, or death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall response rate</measure>
    <time_frame>One year</time_frame>
    <description>overall response rate after treated by R-GemOx or R-miniCHOP overall response rate after treated by R-GemOx or R-miniCHOP regimen</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">258</enrollment>
  <condition>Diffuse Large B Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>R-GemOx</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rituximab: 375 mg/m2 IV day0, Gemcitabine 1g/m2 IV day 1, oxaliplatin 100mg/m2 IV day1(every 14 days)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>R-miniCHOP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Rituximab, 375 mg/m2 IV d0 Cyclophosphamide 400 mg/m2 IV d1 Doxorubicin 25 mg/m2 IV d1 Vincristine 1 mg IVP d1 Prednisone 40mg/m2 PO d1-5(every 21 days a cycle)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>375 mg/m2 IVD day0</description>
    <arm_group_label>R-GemOx</arm_group_label>
    <arm_group_label>R-miniCHOP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Gemcitabine 1 g/m2 IVD day 1</description>
    <arm_group_label>R-GemOx</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>Oxaliplatin 100 mg/m2 IVD day1</description>
    <arm_group_label>R-GemOx</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Cyclophosphamide 400 mg/m2 IVD d1</description>
    <arm_group_label>R-miniCHOP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <description>Doxorubicin 25 mg/m2 IVD d1</description>
    <arm_group_label>R-miniCHOP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristine</intervention_name>
    <description>Vincristine 1 mg IVP d1</description>
    <arm_group_label>R-miniCHOP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>Prednisone 40mg/m2 PO d1-5</description>
    <arm_group_label>R-miniCHOP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologically confirmed diffuse large B cell lymphoma（With exception of Primary
             mediastinal large B cell lymphoma、Primary central nervous system lymphoma、HIV-related
             lymphoma);

          2. New-diagnosed and untreated;

          3. Age older than 80 years or older than 70 years with ECOG PS ≥ 2;

          4. Ann Arbor stage I to stage IV disease;

          5. Understand and voluntarily sign an informed consent form, able to adhere to the study
             visit schedule and other protocol requirements.

        Exclusion Criteria:

          1. Poor hepatic and/or renal function, defined as total bilirubin, ALT, AST, Cr more than
             two fold of upper normal level, unless these abnormalities were related to the
             lymphoma;

          2. Poor bone-marrow reserve, defined as neutrophil count less than 1.5×10⁹/L or platelet
             count less than 100×10⁹/L, unless caused by bone marrow infiltration;

          3. Presence of Grade III nervous toxicity with two weeks;

          4. New York Heart Association class III or IV cardiac failure; or Ejection fraction less
             than 50%;or history of following disease in past 6 months: acute coronary
             syndrome、acute heart failure、severe ventricular arrhythmia

          5. Positive HIV, syphilis,HCV, or HBV virus load(HBV DNA)&gt; 1×10'4copies/ml;

          6. CNS or meningeal involvement;

          7. Concomitant malignancy other than aggressive B cell lymphoma and need to Treat, with
             the exception of non-melanoma skin tumours or stage 0 (in situ) cervical carcinoma,or
             history of cancer more than 5 years;

          8. Concomitant with other hematologic diseases(such as leukemia, hemophilia primary
             myelofibrosis) which investigator it unsuitable to be enrolled into this clinical
             trial;

          9. Active and severe infectious diseases;

         10. Major surgery within three weeks;

         11. Any potential drug abuse, medical, psychological or social conditions which may
             disturb this investigation and assessment.

         12. In any conditions which investigator considered ineligible for this study.

         13. Known sensitivity or allergy to investigational Product.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>70 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wei Xu, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The first Affiliated Hospital Of Nanjing Medical University(JiangSu Province Hospital)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Huayuan Zhu, M.D., Ph.D.</last_name>
    <phone>+86 68136034</phone>
    <email>huayuan.zhu@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Wei Xu, M.D., Ph.D.</last_name>
    <phone>+86 68136034</phone>
    <email>xuwei10000@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Tongji Medical College of HUST</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430030</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jianfeng Zou</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The first Affiliated Hospital Of Nanjing Medical University(JiangSu Province Hospital)</name>
      <address>
        <city>NanJing</city>
        <state>Jiangsu</state>
        <zip>21002</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Huayuan Zhu, M.D., Ph.D.</last_name>
      <phone>+86 68136034</phone>
      <email>huayuan.zhu@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Wei Xu, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>QiLu Hospital of Shandong University</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250012</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luqun Wang, M.D., Ph.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shandong Province Hospital</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xin Wang, M.D., Ph.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rui Jin Hospital Shanghai Jiao Tong University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Weili Zhao, M.D., Ph.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sudan University Shanghai Cancer Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200433</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ye Guo, M.D., Ph.D.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, Salles G, Gaulard P, Reyes F, Lederlin P, Gisselbrecht C. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002 Jan 24;346(4):235-42.</citation>
    <PMID>11807147</PMID>
  </results_reference>
  <results_reference>
    <citation>Oyama T, Yamamoto K, Asano N, Oshiro A, Suzuki R, Kagami Y, Morishima Y, Takeuchi K, Izumo T, Mori S, Ohshima K, Suzumiya J, Nakamura N, Abe M, Ichimura K, Sato Y, Yoshino T, Naoe T, Shimoyama Y, Kamiya Y, Kinoshita T, Nakamura S. Age-related EBV-associated B-cell lymphoproliferative disorders constitute a distinct clinicopathologic group: a study of 96 patients. Clin Cancer Res. 2007 Sep 1;13(17):5124-32.</citation>
    <PMID>17785567</PMID>
  </results_reference>
  <results_reference>
    <citation>Peyrade F, Jardin F, Thieblemont C, Thyss A, Emile JF, Castaigne S, Coiffier B, Haioun C, Bologna S, Fitoussi O, Lepeu G, Fruchart C, Bordessoule D, Blanc M, Delarue R, Janvier M, Salles B, André M, Fournier M, Gaulard P, Tilly H; Groupe d'Etude des Lymphomes de l'Adulte (GELA) investigators. Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2011 May;12(5):460-8. doi: 10.1016/S1470-2045(11)70069-9. Epub 2011 Apr 7.</citation>
    <PMID>21482186</PMID>
  </results_reference>
  <results_reference>
    <citation>López A, Gutiérrez A, Palacios A, Blancas I, Navarrete M, Morey M, Perelló A, Alarcón J, Martínez J, Rodríguez J. GEMOX-R regimen is a highly effective salvage regimen in patients with refractory/relapsing diffuse large-cell lymphoma: a phase II study. Eur J Haematol. 2008 Feb;80(2):127-32. Epub 2007 Nov 20.</citation>
    <PMID>18005385</PMID>
  </results_reference>
  <results_reference>
    <citation>Cabanillas F. Rituximab in DLBCL: 6 years on. Lancet Oncol. 2011 Oct;12(11):984-5. doi: 10.1016/S1470-2045(11)70251-0. Epub 2011 Sep 21.</citation>
    <PMID>21940215</PMID>
  </results_reference>
  <results_reference>
    <citation>Park S, Lee J, Ko YH, Han A, Jun HJ, Lee SC, Hwang IG, Park YH, Ahn JS, Jung CW, Kim K, Ahn YC, Kang WK, Park K, Kim WS. The impact of Epstein-Barr virus status on clinical outcome in diffuse large B-cell lymphoma. Blood. 2007 Aug 1;110(3):972-8. Epub 2007 Mar 30.</citation>
    <PMID>17400912</PMID>
  </results_reference>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 7, 2016</study_first_submitted>
  <study_first_submitted_qc>May 7, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 10, 2016</study_first_posted>
  <last_update_submitted>April 10, 2018</last_update_submitted>
  <last_update_submitted_qc>April 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The First Affiliated Hospital with Nanjing Medical University</investigator_affiliation>
    <investigator_full_name>WEI XU</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>R-Gemox</keyword>
  <keyword>R-miniCHOP</keyword>
  <keyword>elderly patients with diffuse large B cell lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Vincristine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

